carmot glp 1 Therapeutics starts phase 2 trial for CT-868, a GLP-1/GIP agonist, to treat Type Diabetes Efficacy and safety of incretin
Pay in 4 interest-free payments of $7.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




























